can tirzepatide cause heart issues Effects of on circulatory overload and end-organ damage in failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Cardiovascular effects of tirzepatide -

In this article we have highlighted important clinical trial data that support the pharmacotherapy of obesity

In 2022, updated Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommended SGLT2i as first-line therapy for patients with estimated glomerular filtration rate (eGFR) 20 mL/min/1.73 m 2 (previously 30 mL/min/1.73 m 2 ) and GLP-1 RA as an additional therapy option for patients with insufficient glycemic control as part of a comprehensive risk-reduction approach for people with type 2 diabetes and CKD [5, 6, 14]

Peptide is cheaper than treating a soft-tissue infection

The tirzepatide is the same amount regardless

There is solid support for gastroparesis, stomach paralysis, gastrointestinal obstruction, and ileus (bowel obstruction)